Cost-consequence Analysis of Secukinumab vs Adalimumab in Moderate-to-severe Hidradenitis Suppurativa
The results of our financial assessment can help decision makers in selecting the most efficient therapeutic approach for treating patients with moderate-to-severe HS and poses secukinumab as a suitable therapeutic option for the Spanish NHS.
Authors
- A Jiménez Morales
- Antonio Martorell (ORCID: https://orcid.org/0000-0003-1378-1590)
- Carles Blanch
- Alejandro Molina Leyva
Institutions
- Hospital Universitario Virgen de las Nieves (ES)
- Hospital de Manises (ES)
- Novartis (Spain) (ES)
Publication Details
- Journal
- Actas Dermo-Sifiliográficas
- Published
- 2025-12-20
- DOI
- https://doi.org/10.1016/j.ad.2025.104582
- Primary Topic
- Hidradenitis Suppurativa and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00